scholarly journals Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19

Metabolism ◽  
2021 ◽  
Vol 115 ◽  
pp. 154437
Author(s):  
Dong Ji ◽  
Mingjie Zhang ◽  
Enqiang Qin ◽  
Lunqing Zhang ◽  
Jing Xu ◽  
...  
2021 ◽  
Vol 4 (2) ◽  
pp. 99-102
Author(s):  
Hiroshi Bando

The problems among obesity, diabetes mellitus (DM), fatty liver, metabolic dysfunction have been prevalent, and diagnostic criteria as non-alcoholic fatty liver disease (NAFLD) has been used in practice. When diagnosing NAFLD, to exclude other related liver diseases was necessary, including excessive alcohol intake. The international experts proposed the proper term from NAFLD to metabolic associated fatty liver disease (MAFLD). MAFLD criteria include the evidence of the presence of hepatic steatosis associated with three situations. They are obesity/overweight, presence of Type 2 DM (T2DM), or metabolic impaired function, which were studied in the light of pathophysiology, epidemiology, diagnosis and pharmacotherapy.


2020 ◽  
Vol 9 (7) ◽  
pp. 2032 ◽  
Author(s):  
Lauren A. Newman ◽  
Michael J. Sorich ◽  
Andrew Rowland

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately one-third of the global population. Most affected individuals experience only simple steatosis—an accumulation of fat in the liver—but a proportion of these patients will progress to the more severe form of the disease, non-alcoholic steatohepatitis (NASH), which enhances the risk of cirrhosis and hepatocellular carcinoma. Diagnostic approaches to NAFLD are currently limited in accuracy and efficiency; and liver biopsy remains the only reliable way to confirm NASH. This technique, however, is highly invasive and poses risks to patients. Hence, there is an increasing demand for improved minimally invasive diagnostic tools for screening at-risk individuals and identifying patients with more severe disease as well as those likely to progress to such stages. Recently, extracellular vesicles (EVs)—small membrane-bound particles released by virtually all cell types into circulation—have emerged as a rich potential source of biomarkers that can reflect liver function and pathological processes in NAFLD. Of particular interest to the diagnosis and tracking of NAFLD is the potential to extract microRNAs miR-122 and miR-192 from EVs circulating in blood, particularly when using an isolation technique that selectively captures hepatocyte-derived EVs.


2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Vanessa J. Lavallard ◽  
Philippe Gual

Autophagy, or cellular self-digestion, is a catabolic process that targets cell constituents including damaged organelles, unfolded proteins, and intracellular pathogens to lysosomes for degradation. Autophagy is crucial for development, differentiation, survival, and homeostasis. Important links between the regulation of autophagy and liver complications associated with obesity, non-alcoholic fatty liver disease (NAFLD), have been reported. The spectrum of these hepatic abnormalities extends from isolated steatosis to non-alcoholic steatohepatitis (NASH), steatofibrosis, which sometimes leads to cirrhosis, and hepatocellular carcinoma. NAFLD is one of the three main causes of cirrhosis and increases the risk of liver-related death and hepatocellular carcinoma. The pathophysiological mechanisms of the progression of a normal liver to steatosis and then more severe disease are complex and still unclear. The regulation of the autophagic flux, a dynamic response, and the knowledge of the role of autophagy in specific cells including hepatocytes, hepatic stellate cells, immune cells, and hepatic cancer cells have been extensively studied these last years. This review will provide insight into the current understanding of autophagy and its role in the evolution of the hepatic complications associated with obesity, from steatosis to hepatocellular carcinoma.


2021 ◽  
pp. 1-3
Author(s):  
Elizondo Martín ◽  
◽  
Rey Romina and Gerona Solange ◽  

Introduction: Non-alcoholic fatty liver disease affects 1/3 to ¼ of the world’s population. Currently this pathology is being redefined by using the acronym MALFD (Metabolic Dysfunction-Associated Fatty Liver Disease) and the possibility of new criteria for its diagnosis is being discussed. Methodology: Prospective and descriptive studies carried out between July 2018 and June 2020 where the applicability of the new criteria in MAFLD diagnosis were valued. Patients with NAFLD (Non-alcoholic fatty liver disease) were enrolled in clinics specialized in this pathology. Results: Out of 172 patients enrolled, 96.4% (this represents a total of 165 patients) presented obesity, were over weighted and or presented Diabetes Mellitus. The rest of the patients (a total of 7) presented high blood pressure and or dyslipidemia. Moreover, it was observed that the higher the obesity index the higher the prevalence of Diabetes Mellitus. Conclusions: The criteria for the diagnosis of MAFLD are adaptable in patients with a diagnosis of NAFLD from the first consultation and allow the assessment of prognostic elements of the disease. This would allow us to intervene at very early stages which could impact patient’s prognosis


2016 ◽  
Vol 233 (23-24) ◽  
pp. 3947-3952 ◽  
Author(s):  
María José Morlán-Coarasa ◽  
María Teresa Arias-Loste ◽  
Víctor Ortiz-García de la Foz ◽  
Obdulia Martínez-García ◽  
Carmen Alonso-Martín ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document